
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Volagidemab
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Volagidemab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 1.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
February 22, 2024
Lead Product(s) : Volagidemab
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : REMD-477
Therapeutic Area : Endocrinology
Study Phase : Phase II
Recipient : University of California, San Diego
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of GRA in Patients With Type 1
Details : REMD-477 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 1.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 03, 2021
Lead Product(s) : REMD-477
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Recipient : University of California, San Diego
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Volagidemab
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study, which enrolled approximately 150 patients, is a randomized, placebo‑controlled study to evaluate the safety, efficacy, and pharmacodynamics of volagidemab at 35 mg and 70 mg in type 1 diabetes patients who are currently receiving insulin tre...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
January 07, 2021
Lead Product(s) : Volagidemab
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : REMD-477
Therapeutic Area : Endocrinology
Study Phase : Phase I/ Phase II
Recipient : University of California, San Diego
Deal Size : Inapplicable
Deal Type : Inapplicable
Metabolic Pathways of GRA in Patients With Type 1 Diabetes
Details : REMD-477 is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Diabetes Mellitus, Type 1.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 18, 2019
Lead Product(s) : REMD-477
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Recipient : University of California, San Diego
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : REMD-477
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : REMD-477 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 1.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 18, 2017
Lead Product(s) : REMD-477
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : REMD-477
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : REMD-477 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 1.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 22, 2016
Lead Product(s) : REMD-477
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : REMD-477
Therapeutic Area : Endocrinology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : REMD-477 is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 27, 2015
Lead Product(s) : REMD-477
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
